Aspergillosis Superinfection as a Cause of Death of Crizotinib-Induced Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy
Crizotinib is an efficacious and well-tolerated drug in the management of ALK-positive lung cancer. Crizotinib treatment, however, is rarely complicated by the occurrence of acute interstitial lung disease (ILD) that is often fatal. There is no treatment for this serious adverse event. We report a f...
Main Authors: | Laura Deiana, Salvatore Grisanti, Vittorio Ferrari, Andrea Tironi, Giulia Brugnoli, Laura Ferrari, Giordano Bozzola, Alfredo Berruti |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2015-03-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/381209 |
Similar Items
-
Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer
by: Andreia Tereso, et al.
Published: (2019-03-01) -
Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: a case report
by: Shibo Wu, et al.
Published: (2018-07-01) -
Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
by: Emei GAO, et al.
Published: (2016-03-01) -
Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
by: Yuan Cheng, et al.
Published: (2021-03-01) -
Clinical Efficacy of Crizotinib in Advanced ALK Positive
Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)